Revolution Medicines Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Mark Goldsmith
Amministratore delegato
US$10.4m
Compenso totale
| Percentuale dello stipendio del CEO | 6.1% |
| Mandato del CEO | 10yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 6.5yrs |
| Durata media del Consiglio di amministrazione | 7.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)
Sep 28
This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate
Jun 15Revolution Medicines: On Hold Pending A Lower Entry Point
Jun 04Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Apr 12Revolution Medicines Is Hard To Understand
Feb 01Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation
Aug 09Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates
May 13We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
Apr 02We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Dec 20We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Sep 15Revolution Medicines promotes Jack Anders to CFO
Sep 02New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)
Aug 10Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$567m |
| Jun 30 2024 | n/a | n/a | -US$519m |
| Mar 31 2024 | n/a | n/a | -US$484m |
| Dec 31 2023 | US$10m | US$631k | -US$436m |
| Sep 30 2023 | n/a | n/a | -US$331m |
| Jun 30 2023 | n/a | n/a | -US$296m |
| Mar 31 2023 | n/a | n/a | -US$259m |
| Dec 31 2022 | US$7m | US$607k | -US$249m |
| Sep 30 2022 | n/a | n/a | -US$245m |
| Jun 30 2022 | n/a | n/a | -US$224m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$8m | US$581k | -US$187m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$143m |
| Mar 31 2021 | n/a | n/a | -US$126m |
| Dec 31 2020 | US$2m | US$554k | -US$110m |
| Sep 30 2020 | n/a | n/a | -US$95m |
| Jun 30 2020 | n/a | n/a | -US$85m |
| Mar 31 2020 | n/a | n/a | -US$71m |
| Dec 31 2019 | US$5m | US$504k | -US$62m |
| Sep 30 2019 | n/a | n/a | -US$57m |
| Dec 31 2018 | US$1m | US$490k | -US$49m |
Compensazione vs Mercato: La retribuzione totale di Mark ($USD 10.41M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 7.74M ).
Compensazione vs guadagni: La retribuzione di Mark è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Mark Goldsmith (62 yo)
10yrs
Mandato
US$10,411,247
Compensazione
Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Par...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Chairman | 10yrs | US$10.41m | 0.39% $ 37.1m | |
| Chief Financial Officer | 6.3yrs | US$3.05m | 0.029% $ 2.8m | |
| Chief Operating Officer | 6.1yrs | US$4.39m | 0.033% $ 3.1m | |
| President of Research & Development | 7.7yrs | US$4.39m | 0.11% $ 10.1m | |
| Executive Vice President of Development | 6.7yrs | US$3.23m | 0.015% $ 1.5m | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Academic Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.9yrs | Nessun dato | Nessun dato | |
| Chief Information Officer | no data | Nessun dato | Nessun dato | |
| Chief Scientific Officer | 1.3yrs | Nessun dato | Nessun dato | |
| Senior Director of Corporate Communications & Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior VP | 2.2yrs | Nessun dato | 0.0017% $ 163.2k |
6.5yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di RVMD è esperto e expertise (durata media dell'incarico 6.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Chairman | 10yrs | US$10.41m | 0.39% $ 37.1m | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Academic Co-Founder & Member of Scientific Advisory Board | 8.4yrs | Nessun dato | Nessun dato | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.9yrs | Nessun dato | Nessun dato | |
| Senior Advisor & Member of Scientific Advisory Board | 7.9yrs | Nessun dato | Nessun dato | |
| Lead Independent Director | 10yrs | US$510.63k | 1.39% $ 132.3m | |
| Senior Advisor & Member of Scientific Advisory Board | 8.4yrs | Nessun dato | Nessun dato | |
| Senior Advisor & Member of Scientific Advisory Board | 7.9yrs | Nessun dato | Nessun dato | |
| Independent Director | 2.3yrs | US$489.99k | 0.036% $ 3.5m | |
| Independent Director | 6.7yrs | Nessun dato | Nessun dato | |
| Independent Director | 9.7yrs | US$483.78k | 0.025% $ 2.4m | |
| Senior Advisor & Member of Scientific Advisory Board | 7.9yrs | Nessun dato | Nessun dato |
7.9yrs
Durata media
52yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RVMD sono considerati esperti (durata media dell'incarico 7.9 anni).